No Data
No Data
Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays c
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $9
Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs with a Buy and lowers the price target from $21 to $9.
Rani Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Rani Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Buy Rating for Rani Therapeutics: Promising Clinical Data and Significant Market Potential
Express News | HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $12
No Data
Chasing_Freedom : Hate mfs like u